Gyre Therapeutics Common Stock share price logo

Gyre Therapeutics Common Stock

NASDAQ: GYRE

Small Cap

$6.13

as on

Gyre Therapeutics Common Stock Stock Performance

as on June 24, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $6.10
    $6.25
    downward going graph

    0.49%

    Downside

    1.96%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $5.44
    $9.42
    downward going graph

    11.26%

    Downside

    53.67%

    Upside

    downward going graph

Gyre Therapeutics Common Stock share price movements today

Previous Close
$6.13
Open
$6.24
Volume
122.9K
Day's Low - High
$6.10 - $6.25
52 Week Low - High
$5.44 - $9.42

Gyre Therapeutics Common Stock Historical Returns

1 Month Return
+ 1.16 %
3 Month Return
-11.67 %
1 Year Return
-19.45 %
3 Year Return
0 %
5 Year Return
0 %

Gyre Therapeutics Common Stock Stock Fundamentals & Key Indicators

Check Gyre Therapeutics Common Stock market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$594.8M

EPS (TTM)

-0.29

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

1.66%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

5.1M

Revenue (TTM)

117.0M

Profit Margin

-5.44%

Return On Equity TTM

-3.08%

Gyre Therapeutics Common Stock vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Gyre Therapeutics Common Stock with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Gyre Therapeutics Common Stock image
Gyre Therapeutics Common Stock
SELL$594.8MNANA-5.44%NA
Alnylam Pharmaceuticals Common Stock image
Alnylam Pharmaceuticals Common Stock
BUY$38.2B65.93%71.9612.55%NA
Vertex PharmaceuticalsCommon Stock image
Vertex PharmaceuticalsCommon Stock
BUY$118.5B144.05%27.735.51%NA
Regeneron Pharmaceuticals Common Stock image
Regeneron Pharmaceuticals Common Stock
BUY$64.2B13.51%14.9529.65%0.59%

Stock Returns calculator for Gyre Therapeutics Common Stock Stock including INR - Dollar returns

The Gyre Therapeutics Common Stock stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

Gyre Therapeutics Common Stock investment value today

Current value as on today

₹88,139

Returns

-₹11,861

(-11.86%)

Returns from Gyre Therapeutics Common Stock Stock

-₹19,448 (-19.45%)

Dollar Impact

₹7,587 (+7.59%)

Analyst Recommendation on Gyre Therapeutics Common Stock Stock

Based on 6 analysts

SELL

0.00%

Buy

50.00%

Hold

50.00%

Sell

Based on 6 analysts, 50% of analysts recommend a 'SELL' rating for Gyre Therapeutics Common Stock. Average target price of $18.67

Gyre Therapeutics Common Stock Share Price Target

Get share price movements and forecasts by analysts on Gyre Therapeutics Common Stock.

What analysts predicted

67.17%UPSIDE

Target Price

$18.67

Current Price

$6.13

Analyzed by

6 Analysts

Target

$18.67

Gyre Therapeutics Common Stock target price $18.67, a slight upside of 67.17% compared to current price of $6.13. According to 6 analysts rating.

Indian Investors' Interest in Gyre Therapeutics Common Stock Stock

Search interest for Gyre Therapeutics Common Stock Stock has decreased by -38% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-38% versus previous 30 day period

Gyre Therapeutics Common Stock Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
27
27
25
25
27
22
26
30
37
22
Gross Profit
25
26
24
24
26
21
25
28
35
21
Operating Income
-91
8
3
4
0
2
2
6
0
-9
EBITDA
-4
12
6
4
1
5
2
8
0
-8
Interest Expense
-
-
-
-
0
-
-
1
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-100
12
6
3
0
4
2
7
0
-9
Income Tax Expense
0
2
1
1
0
0
0
1
1
0
Net Income
-101
7
3
1
0
2
0
3
-1
-8
Net Profit Margin
-372.06%
27.72%
13.99%
4.41%
-0.36%
12.23%
1.65%
11.81%
-4.63%
-38.26%

Gyre Therapeutics Common Stock Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
1
0
20
1
14
113
105
116
Gross Profit
-10
-11
-21
11
0
13
108
101
111
Operating Income
-20
-21
-33
-57
-83
9
-67
16
11
EBITDA
-16
-21
-33
-56
-87
10
20
17
16
Interest Expense
-
-
-
-
0
0
-
-
-
Depreciation
-
-
-
-
1
1
1
1
2
Income Before Tax
-16
-21
-30
-56
-87
9
-76
23
14
Income Tax Expense
3
0
3
0
0
5
8
5
4
Net Income
-16
-21
-30
-55
-13
0
-92
12
5
Net Profit Margin
-4246.87%
-2117.98%
-500916.67%
-265.14%
-1198.32%
2.25%
-81.92%
11.43%
4.31%

Gyre Therapeutics Common Stock Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
9
3
1
0
3
1
5
-2
-8
Operating Cash Flow
2
-5
1
-2
0
2
4
-5
3
Investing Cash Flow
-7
-8
-2
-2
1
-3
-1
1
-3
Financing Cash Flow
0
0
0
0
1
22
0
0
0
Change in Cash
-3
-13
0
-4
3
21
3
-3
0

Gyre Therapeutics Common Stock Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-21
-30
-55
-56
-87
4
-85
17
9
Operating Cash Flow
-19
-28
-43
-55
-83
10
25
-3
1
Investing Cash Flow
-11
-71
27
9
48
-13
-19
-19
0
Financing Cash Flow
35
111
0
60
49
-45
2
2
24
Change in Cash
4
11
-15
14
13
-5
8
-21
25

Global Institutional Holdings in Gyre Therapeutics Common Stock

Funds
Holdings
Vanguard Portfolio Management, LLC
0.07%
State Of Wisconsin Investment Board
0.03%
AllianceBernstein L.P.
0.02%
FMR Inc
0.02%
Brevan Howard Capital Management LP
0.01%
See all

Insights on Gyre Therapeutics Common Stock

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Regeneron Pharmaceuticals, Inc. Common Stock has given 18.3% return, outperforming this stock by 37.7%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, GYRE stock has moved down by -11.7%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 37.19M → 22.51M (in $), with an average decrease of 39.5% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, 3.61M → -8.61M (in $), with an average decrease of 273.9% per quarter

About Gyre Therapeutics Common Stock

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
OrganisationGyre Therapeutics Common Stock
Headquarters12730 High Bluff Drive, San Diego, CA, United States, 92130
IndustryBiotechnology
CEODr. Ying Luo Ph.D.
E-voting on sharesClick here to vote

Key Management of Gyre Therapeutics Common Stock

Name

Title

Ms. Ruoyu Chen

Chief Information Officer

Dr. Ying Luo Ph.D.

CEO, President & Director

Mr. Joshua Bergmann J.D.

General Counsel & Corporate Secretary

Seth Goldblum M.B.A.

Senior Vice President of Corporate Development

Mr. Jialiang Wang Ph.D.

Executive VP & GM

Mark Marino

Senior Vice President of Clinical Development

Mr. Thomas W. Eastling M.D.

Chief Financial Officer

Mr. Weiguo Ye

Chief Operating Officer

Dr. Yue Xiong Ph.D.

Chief Scientific Officer

Jing Liu Ph.D.

Senior Vice President of Platform Chemistry

FAQs

What is Gyre Therapeutics Common Stock share price today?

Gyre Therapeutics Common Stock share price today is $6.13 as on at the close of the market. Gyre Therapeutics Common Stock share today touched a day high of $6.25 and a low of $6.1.

What is the 52 week high and 52 week low for Gyre Therapeutics Common Stock share?

Gyre Therapeutics Common Stock share touched a 52 week high of $9.42 on and a 52 week low of $5.44 on . Gyre Therapeutics Common Stock stock price today i.e. is closed at $6.13,which is 34.93% down from its 52 week high and 12.68% up from its 52 week low.

What is Gyre Therapeutics Common Stock's market capitalisation today?

Gyre Therapeutics Common Stock market capitalisation is $0.00T as on .

How to invest in Gyre Therapeutics Common Stock Stock (GYRE) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Gyre Therapeutics Common Stock on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Gyre Therapeutics Common Stock Shares that will get you 0.2447 shares as per Gyre Therapeutics Common Stock share price of $6.13 per share as on June 24, 2026 at 8:45 am IST.

What is the minimum amount required to buy Gyre Therapeutics Common Stock Stock (GYRE) from India?

Indian investors can start investing in Gyre Therapeutics Common Stock (GYRE) shares with as little as ₹94.735 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹947.35 in Gyre Therapeutics Common Stock stock (as per the Rupee-Dollar exchange rate as on ). Based on Gyre Therapeutics Common Stock share’s latest price of $6.13 as on June 24, 2026 at 8:45 am IST, you will get 1.6313 shares of Gyre Therapeutics Common Stock. Learn more about fractional shares .